TH11644C3 - Melatonin liquid pills - Google Patents
Melatonin liquid pillsInfo
- Publication number
- TH11644C3 TH11644C3 TH1503001717U TH1503001717U TH11644C3 TH 11644 C3 TH11644 C3 TH 11644C3 TH 1503001717 U TH1503001717 U TH 1503001717U TH 1503001717 U TH1503001717 U TH 1503001717U TH 11644 C3 TH11644 C3 TH 11644C3
- Authority
- TH
- Thailand
- Prior art keywords
- melatonin
- weight
- glycerin
- sodium deoxycholate
- encapsulation
- Prior art date
Links
- 229960003987 Melatonin Drugs 0.000 title claims abstract 10
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title claims abstract 10
- 239000007788 liquid Substances 0.000 title claims abstract 4
- 239000006187 pill Substances 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical class C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract 6
- KXGVEGMKQFWNSR-LLQZFEROSA-N Deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims abstract 4
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract 4
- 229960003964 deoxycholic acid Drugs 0.000 claims abstract 4
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 4
- -1 polyoxymethylene Chemical class 0.000 claims abstract 4
- 229940107161 Cholesterol Drugs 0.000 claims abstract 3
- 235000012000 cholesterol Nutrition 0.000 claims abstract 3
- 150000003904 phospholipids Chemical class 0.000 claims abstract 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract 2
- 239000008367 deionised water Substances 0.000 claims abstract 2
- 239000012153 distilled water Substances 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 239000000796 flavoring agent Substances 0.000 claims abstract 2
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract 2
- 229920002866 paraformaldehyde Chemical class 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 2
- NJTGANWAUPEOAX-UHFFFAOYSA-N MolPort-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 Xylitol Drugs 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- 235000011187 glycerol Nutrition 0.000 abstract 2
- 238000001959 radiotherapy Methods 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract 1
- 210000000214 Mouth Anatomy 0.000 abstract 1
- 210000002200 Mouth Mucosa Anatomy 0.000 abstract 1
- 210000003296 Saliva Anatomy 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000000857 drug effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 229960005181 morphine Drugs 0.000 abstract 1
- 229930014694 morphine Natural products 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 239000002353 niosome Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 231100000486 side effect Toxicity 0.000 abstract 1
Abstract
ยาน้ำเมลาโทนิน มีส่วนประกอบ คือ เมลาโทนิน (melatonin), คอเลสเตอรอล (cholesterol), ฟอสฟอสิปิด(phospholipid) หรืออนุพันธ์ของพอลิออกซิเอทิลิน (polyoxyethylene derivatives), โซเดียมดิออกซิโคเลท (sodium deoxycholate), พอลิเอทิลีนไกลคอล (PEG400), กลีเซอรีน (Glycerin),สารแต่งรส,สารแต่งกลิ่น และน้ำกลั่นหรือน้ำปราศจากอิออน โดยยาน้ำเมลาโทนินใช้สำเคลือบเยื่อบุอ่อนในช่องปาก เพื่อช่วยลดอาการข้างเคียงจาก การฉายรังสีรักษาและเคมีบำบัด อาทิ อาการอักเสบของแผลเยื่อบุอ่อนในช่องปาก และอาการน้ำลาย แห้งในผู้ที่ได้รับรังสีรักษา รวมทั้งช่วยลดปริมาณการใช้ยาแก้ปวดมอร์ฟินในผู้ป่วยได้ ซึ่งเมลาโทนินที่ใช้ มีความเข้มข้นระหว่าง 1-8% อาศัยหลักการเอนแคปซูเลชัน (Encapsulation) ทำให้เมลาโทนินบรรจุใน อนุภาคไลโปโซมหรือไนโอโซม เพื่อเพิ่มความคงตัวในยาน้ำตามการประดิษฐ์นี้ และช่วยในการนำส่งตัว ยาให้ออกฤทธิ์เฉพาะที่นานขึ้น รวมถึงช่วยกลบรสของเมลาโทนินได้ Melatonin tablets contain melatonin, cholesterol, phospholipid or polyoxymethylene derivatives. (polyoxyethylene derivatives), sodium deoxycholate (sodium deoxycholate), polyethylene glycol (PEG400), glycerin (Glycerin), flavoring, flavoring agent. And distilled or deionized water By melatonin liquid used to coat the soft mucosa in the oral cavity To help reduce side effects from Radiation therapy and chemotherapy, such as inflammation of the oral mucosa And saliva Dryness in people receiving radiotherapy As well as help reduce the amount of morphine painkiller use in patients Which melatonin is used There is a concentration between 1-8% based on the principle of encapsulation. (Encapsulation) makes melatonin contained in Liposome particles or niosomes To increase the stability of the liquid medicine according to this invention And help in delivering Long-lasting drug effect Including helping to cover the taste of melatonin
Claims (1)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH11644C3 true TH11644C3 (en) | 2016-06-09 |
| TH11644A3 TH11644A3 (en) | 2016-06-09 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ605887A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain | |
| MX2016015179A (en) | A liquid formulation comprising nicotine for aerosol administration. | |
| MX2022003072A (en) | Use of pridopidine for treating functional decline. | |
| EA201491285A1 (en) | IMPROVED COMPOSITIONS AND METHODS OF DELIVERY OF OMEPRAZOL AND ACETYLSALICYLIC ACID | |
| PE20160195A1 (en) | USE OF PRIDOPIDINE IN HIGH DOSES FOR THE TREATMENT OF HUNTINGTON DISEASE | |
| JP2017506624A5 (en) | ||
| NZ715686A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
| DE602008006700D1 (en) | ||
| AR080096A1 (en) | COMBINED TREATMENT OF PANCREAS CANCER WITH GEMCITABIN AND MASITINIB | |
| IL254641B2 (en) | Methods and compositions comprising naproxen and fexofenadine to inhibit symptoms of dizziness associated with intake of alcohol | |
| EA201391689A1 (en) | SYSTEM OF DELIVERY MEDICINE | |
| MX2016016400A (en) | Stabilized oxymetazoline formulations and their uses. | |
| EA201591415A1 (en) | PHARMACEUTICAL COMPOSITIONS, INCLUDING MULTICOMPONENT CRYSTALLINE PARTICLES, SUITABLE FOR USE IN INHALATION THERAPY | |
| MX2015016418A (en) | Dihydroetorphine for the provision of pain relief and anaesthesia. | |
| TH11644C3 (en) | Melatonin liquid pills | |
| TH11644A3 (en) | Melatonin liquid pills | |
| MX2020003697A (en) | Pharmaceutical formulations comprising opioid receptor agonist as active ingredients, methods of manufacture and therapeutic uses thereof. | |
| EA201590847A1 (en) | NEW ROCK INHIBITORS | |
| MX2018005876A (en) | Plasminogen dosage regimen for wound healing. | |
| ATE546133T1 (en) | ORAL DOSAGE FORM WITH TRIS-SUBSTITUTED GLYCERIN COMPOUNDS | |
| CY1120282T1 (en) | PHARMACEUTICAL COMPOSITION OF SILDENAFIL CITRUS IN THE FORM OF AN ORAL DRIVE FOR USE | |
| WO2014184726A3 (en) | Compounds and their use in therapy | |
| EA201491995A1 (en) | ORAL MEDICAL FORM | |
| JP2015515971A5 (en) | ||
| RU2014101958A (en) | PHARMACEUTICAL COMPOSITION FOR TREATING DEPENDENCE IN PEOPLE |